How TNXP (Tonix Pharmaceuticals Holding) Makes Money in 2025: A Deep-Dive With Income Statement

Welcome to the Value Sense Blog, your resource for insights on the stock market! At Value Sense, we focus on intrinsic value tools and offer stock ideas with undervalued companies. Dive into our research products and learn more about our unique approach at valuesense.io

Explore diverse stock ideas covering technology, healthcare, and commodities sectors. Our insights are crafted to help investors spot opportunities in undervalued growth stocks, enhancing potential returns. Visit us to see evaluations and in-depth market research.

Understanding how a biotechnology company like TNXP Income Statement Overview makes money is essential for investors and anyone interested in the business of healthcare innovation. In this post, we break down TNXP's quarterly income statement (Q2 2025) using a Sankey chart to visualize the financial flows — what comes in, where it goes, and what's left as profit.

Quick TNXP Overview

TNXP Income Statement Overview operates as a biotechnology firm focused on developing innovative therapeutics targeting neurological and psychiatric disorders. Revenue comes primarily from licensing agreements, research grants, and milestone payments associated with its drug development pipeline. The company does not yet have significant product sales, as its main candidates are in clinical development.

Revenue Breakdown

• Total Revenue (Q2 2025): $2.0M (-9.5% YoY)
  • Licensing & Grants: $2.0M (100% of total)
  • Product Sales: $0M (0% of total)
  • Growth is powered by ongoing research collaborations and new grant awards, though overall revenue declined YoY due to timing of milestone payments.

Gross Profit and Margins

• Gross Profit: $1.3M (63.8% gross margin)
  • Cost of Revenue: $3.3M (-2.8% YoY)
  • TNXP maintains moderate margins due to its focus on high-value research activities and efficient grant utilization.
• Most costs come from clinical trial expenses, research materials, and personnel costs.

Operating Income and Expenses

• Operating Income: Not reported for Q2 2025 (operating loss implied due to high expenses)
• Operating Expenses: $27.0M (+571.0% YoY)
  • R&D: $10.8M (+11.6% YoY, 541.5% of revenue) — Investment in late-stage clinical trials, regulatory submissions, and expanding the drug pipeline.
  • SG&A: $16.2M (+116.0% YoY, 810.9% of revenue) — Includes executive compensation, legal, compliance, and marketing for future product launches.
  • TNXP continues to prioritize innovation and invest in growth, with a substantial ramp-up in operating expenses as clinical programs advance.

Net Income

• Pre-Tax Income: Not reported for Q2 2025 (pre-tax loss implied)
• Income Tax: Not reported (no taxable income due to operating losses)
• Net Income: Not reported for Q2 2025 (net loss implied)
• TNXP converts a minimal portion of sales into profit due to the heavy investment phase typical for biotech firms pre-commercialization.

What Drives TNXP's Money Machine?

• Licensing & Grant Revenue: 100% of revenue, reflecting TNXP's reliance on external funding and partnerships rather than product sales.
• R&D Intensity: R&D expenses are over 5x total revenue, highlighting the company's commitment to advancing its pipeline.
• Strategic Investments: Focused on clinical trial progression, regulatory filings, and expanding therapeutic indications.
• Future Growth Areas: Commercialization of lead drug candidates and expansion into new indications, though these segments are not yet profitable.

Visualizing TNXP's Financial Flows

The Sankey chart below visualizes how each dollar flows from gross revenue, through costs and expenses, down to net income. This helps investors spot where value is created, what areas weigh on profits, and how efficiently the company operates.

• Most revenue flows into gross profit, with operating expenses (especially R&D and SG&A) taking the largest chunk.
• Even after large investments in research and administration, TNXP's revenue is insufficient to cover expenses, resulting in an operating loss.

Key Takeaways

• TNXP's money comes overwhelmingly from licensing agreements and research grants
• High gross margins illustrate the power of TNXP's research-driven business model, but net margins are negative due to heavy investment
• Heavy investment in R&D and SG&A, balanced by efficient grant utilization
• Ongoing growth is driven by pipeline advancement and strategic partnerships

Explore More Investment Opportunities

For investors seeking undervalued companies with high fundamental quality, our analytics team provides curated stock lists:

📌 50 Undervalued Stocks (Best) overall value plays for 2025
📌 50 Undervalued Dividend Stocks (For income-focused investors)
📌 50 Undervalued Growth Stocks (High-growth potential with strong fundamentals)

🔍 Check out these stocks on the Value Sense platform for free!

FAQ About TNXP's Income Statement

1. What is the main source of TNXP's revenue in 2025?

TNXP generates over 100% of its revenue from licensing agreements and research grants. There are no significant product sales as the company is still in the clinical development phase.

2. How profitable is TNXP in Q2 2025?

TNXP reported no net income in Q2 2025, with a net margin well below zero, reflecting moderate profitability at the gross level but significant operating losses driven by high R&D and SG&A expenses.

3. What are the largest expense categories for TNXP?

The biggest expenses on TNXP's income statement are operating expenses, particularly Research & Development (R&D) at $10.8M and Sales, General & Administrative (SG&A) at $16.2M in Q2 2025. R&D investment is focused on clinical trials and pipeline expansion.

4. Why does the R&D segment operate at a loss?

R&D, despite being the core of TNXP's business, posted an operating loss of over $10.8M in Q2 2025. This is because TNXP aggressively invests in clinical development and regulatory filings, believing these will drive long-term growth—even if the division is unprofitable today.

5. How does TNXP's effective tax rate compare to previous years?

TNXP's effective tax rate in Q2 2025 was not reported, consistent with previous years where operating losses preclude significant tax liabilities. This low rate is primarily due to ongoing net losses and utilization of tax credits for R&D.